Galacto-oligosaccharides may directly enhance intestinal barrier function through the modulation of goblet cells

Shikha Bhatia, P. Nagendra Prabhu, Ann C. Benefiel, Michael J Miller, Jomay Chow, Steven R. Davis, H Rex Gaskins

Research output: Contribution to journalArticle

Abstract

Scope: Here we have tested the hypothesis that prebiotic galacto-oligosaccharides (GOS) may enhance mucosal barrier function through direct modulation of goblet cell function. Methods and results: Human adenocarcinoma-derived LS174T cells, which exhibit an intestinal goblet cell-like phenotype, were used to examine the non-prebiotic effects of GOS on goblet cell functions. LS174T cells were treated with GOS, and the expression of goblet cell secretory product genes mucin 2 (MUC2), trefoil factor 3 (TFF3), resistin-like molecule beta (RETNLB) and the Golgi-sulfotransferase genes, carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 5 (CHST5) and galactose-3-O-sulfotransferase 2 (GAL3ST2), was determined by real-time quantitative RT-PCR. In addition, the abundance of CHST5, TFF3 and RETNLB was confirmed by Western blot analysis. Following treatment with GOS for 72 h, the expression of MUC2 was significantly upregulated 2-4-fold, CHST5 and RETNLB, 5-7-fold, and TFF3 2-4-fold. Western blot analysis demonstrated increased abundance of RETNLB, TFF3 and CHST5. Addition of the Th2 cytokine IL-13 along with GOS resulted in synergistic induction of RETNLB and CHST5. IL-8 secretion was not affected by GOS treatment, suggesting that the effects of GOS are not mediated through an inflammatory pathway. Conclusion: Collectively, the data indicate that GOS may enhance mucosal barrier function through direct stimulation of intestinal goblet cells.

Original languageEnglish (US)
Pages (from-to)566-573
Number of pages8
JournalMolecular Nutrition and Food Research
Volume59
Issue number3
DOIs
StatePublished - Mar 1 2015

Fingerprint

galactooligosaccharides
Goblet Cells
goblet cells
Oligosaccharides
resistin
Resistin
sulfotransferases
Mucin-2
mucins
Western blotting
Western Blotting
Sulfotransferases
Prebiotics
N-acetylglucosamine
Interleukin-13
Acetylglucosamine
interleukin-8
prebiotics
adenocarcinoma
Interleukin-8

Keywords

  • Galacto-oligosaccharides
  • Golgi-sulfotransferases
  • LS174T goblet cells
  • RELMβ
  • RETNLB

ASJC Scopus subject areas

  • Biotechnology
  • Food Science

Cite this

Galacto-oligosaccharides may directly enhance intestinal barrier function through the modulation of goblet cells. / Bhatia, Shikha; Prabhu, P. Nagendra; Benefiel, Ann C.; Miller, Michael J; Chow, Jomay; Davis, Steven R.; Gaskins, H Rex.

In: Molecular Nutrition and Food Research, Vol. 59, No. 3, 01.03.2015, p. 566-573.

Research output: Contribution to journalArticle

Bhatia, Shikha ; Prabhu, P. Nagendra ; Benefiel, Ann C. ; Miller, Michael J ; Chow, Jomay ; Davis, Steven R. ; Gaskins, H Rex. / Galacto-oligosaccharides may directly enhance intestinal barrier function through the modulation of goblet cells. In: Molecular Nutrition and Food Research. 2015 ; Vol. 59, No. 3. pp. 566-573.
@article{fb85beec21b34e59bf27bb3434644ee2,
title = "Galacto-oligosaccharides may directly enhance intestinal barrier function through the modulation of goblet cells",
abstract = "Scope: Here we have tested the hypothesis that prebiotic galacto-oligosaccharides (GOS) may enhance mucosal barrier function through direct modulation of goblet cell function. Methods and results: Human adenocarcinoma-derived LS174T cells, which exhibit an intestinal goblet cell-like phenotype, were used to examine the non-prebiotic effects of GOS on goblet cell functions. LS174T cells were treated with GOS, and the expression of goblet cell secretory product genes mucin 2 (MUC2), trefoil factor 3 (TFF3), resistin-like molecule beta (RETNLB) and the Golgi-sulfotransferase genes, carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 5 (CHST5) and galactose-3-O-sulfotransferase 2 (GAL3ST2), was determined by real-time quantitative RT-PCR. In addition, the abundance of CHST5, TFF3 and RETNLB was confirmed by Western blot analysis. Following treatment with GOS for 72 h, the expression of MUC2 was significantly upregulated 2-4-fold, CHST5 and RETNLB, 5-7-fold, and TFF3 2-4-fold. Western blot analysis demonstrated increased abundance of RETNLB, TFF3 and CHST5. Addition of the Th2 cytokine IL-13 along with GOS resulted in synergistic induction of RETNLB and CHST5. IL-8 secretion was not affected by GOS treatment, suggesting that the effects of GOS are not mediated through an inflammatory pathway. Conclusion: Collectively, the data indicate that GOS may enhance mucosal barrier function through direct stimulation of intestinal goblet cells.",
keywords = "Galacto-oligosaccharides, Golgi-sulfotransferases, LS174T goblet cells, RELMβ, RETNLB",
author = "Shikha Bhatia and Prabhu, {P. Nagendra} and Benefiel, {Ann C.} and Miller, {Michael J} and Jomay Chow and Davis, {Steven R.} and Gaskins, {H Rex}",
year = "2015",
month = "3",
day = "1",
doi = "10.1002/mnfr.201400639",
language = "English (US)",
volume = "59",
pages = "566--573",
journal = "Molecular Nutrition and Food Research",
issn = "1613-4125",
publisher = "Wiley-VCH Verlag",
number = "3",

}

TY - JOUR

T1 - Galacto-oligosaccharides may directly enhance intestinal barrier function through the modulation of goblet cells

AU - Bhatia, Shikha

AU - Prabhu, P. Nagendra

AU - Benefiel, Ann C.

AU - Miller, Michael J

AU - Chow, Jomay

AU - Davis, Steven R.

AU - Gaskins, H Rex

PY - 2015/3/1

Y1 - 2015/3/1

N2 - Scope: Here we have tested the hypothesis that prebiotic galacto-oligosaccharides (GOS) may enhance mucosal barrier function through direct modulation of goblet cell function. Methods and results: Human adenocarcinoma-derived LS174T cells, which exhibit an intestinal goblet cell-like phenotype, were used to examine the non-prebiotic effects of GOS on goblet cell functions. LS174T cells were treated with GOS, and the expression of goblet cell secretory product genes mucin 2 (MUC2), trefoil factor 3 (TFF3), resistin-like molecule beta (RETNLB) and the Golgi-sulfotransferase genes, carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 5 (CHST5) and galactose-3-O-sulfotransferase 2 (GAL3ST2), was determined by real-time quantitative RT-PCR. In addition, the abundance of CHST5, TFF3 and RETNLB was confirmed by Western blot analysis. Following treatment with GOS for 72 h, the expression of MUC2 was significantly upregulated 2-4-fold, CHST5 and RETNLB, 5-7-fold, and TFF3 2-4-fold. Western blot analysis demonstrated increased abundance of RETNLB, TFF3 and CHST5. Addition of the Th2 cytokine IL-13 along with GOS resulted in synergistic induction of RETNLB and CHST5. IL-8 secretion was not affected by GOS treatment, suggesting that the effects of GOS are not mediated through an inflammatory pathway. Conclusion: Collectively, the data indicate that GOS may enhance mucosal barrier function through direct stimulation of intestinal goblet cells.

AB - Scope: Here we have tested the hypothesis that prebiotic galacto-oligosaccharides (GOS) may enhance mucosal barrier function through direct modulation of goblet cell function. Methods and results: Human adenocarcinoma-derived LS174T cells, which exhibit an intestinal goblet cell-like phenotype, were used to examine the non-prebiotic effects of GOS on goblet cell functions. LS174T cells were treated with GOS, and the expression of goblet cell secretory product genes mucin 2 (MUC2), trefoil factor 3 (TFF3), resistin-like molecule beta (RETNLB) and the Golgi-sulfotransferase genes, carbohydrate (N-acetylglucosamine-6-O) sulfotransferase 5 (CHST5) and galactose-3-O-sulfotransferase 2 (GAL3ST2), was determined by real-time quantitative RT-PCR. In addition, the abundance of CHST5, TFF3 and RETNLB was confirmed by Western blot analysis. Following treatment with GOS for 72 h, the expression of MUC2 was significantly upregulated 2-4-fold, CHST5 and RETNLB, 5-7-fold, and TFF3 2-4-fold. Western blot analysis demonstrated increased abundance of RETNLB, TFF3 and CHST5. Addition of the Th2 cytokine IL-13 along with GOS resulted in synergistic induction of RETNLB and CHST5. IL-8 secretion was not affected by GOS treatment, suggesting that the effects of GOS are not mediated through an inflammatory pathway. Conclusion: Collectively, the data indicate that GOS may enhance mucosal barrier function through direct stimulation of intestinal goblet cells.

KW - Galacto-oligosaccharides

KW - Golgi-sulfotransferases

KW - LS174T goblet cells

KW - RELMβ

KW - RETNLB

UR - http://www.scopus.com/inward/record.url?scp=84924015110&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84924015110&partnerID=8YFLogxK

U2 - 10.1002/mnfr.201400639

DO - 10.1002/mnfr.201400639

M3 - Article

C2 - 25421108

AN - SCOPUS:84924015110

VL - 59

SP - 566

EP - 573

JO - Molecular Nutrition and Food Research

JF - Molecular Nutrition and Food Research

SN - 1613-4125

IS - 3

ER -